Genetic polymorphisms of adhesion molecules and kidney transplant survival

Transplantation

Volumn 89, Issue 9, 2010, Pages 1079-1087

  Heinold, Andreas ^a   Opelz, Gerhard ^a   Döhler, Bernd ^a   Scherer, Sabine ^a   Ruhenstroth, Andrea ^a   Tran, Thuong Hien ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adhesion molecules; Genetic polymorphisms; Kidney transplantation

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD31 ANTIGEN; DNA; L SELECTIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ADULT; ANTIGENS, CD31; CADAVER; CODON; DATABASES, NUCLEIC ACID; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT SURVIVAL; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; L-SELECTIN; MALE; MIDDLE AGED; PATIENT SELECTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77951877793     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181d3c9ee     Document Type: Article

References (50)

1. Kelly M, Hwang JM, Kubes P. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007; 120: 3.
2. Tedder TF, Steeber DA, Chen A, et al. The selectins: Vascular adhesion molecules. FASEB J 1995; 9: 866.
3. Vestweber D. Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol Rev 2007; 218: 178.
4. Liao F, Ali J, Greene T, et al. Soluble domain 1 of platelet-endothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo. J Exp Med 1997; 185: 1349.
5. Liao F, Schenkel AR, Muller WA. Transgenic mice expressing different levelsofsoluble platelet/endothelial cell adhesion molecule-IgG display distinct inflammatory phenotypes. J Immunol 1999; 163: 5640.
6. Muller WA, Weigl SA, Deng X, et al. PECAM-1 is required for trans-endothelial migration of leukocytes. J Exp Med 1993; 178: 449.
7. Masedunskas A, King JA, Tan F, et al. Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in trans-endothelial monocyte migration. FEBS Lett 2006; 580: 2637.
8. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: A molecular machine controlling T cell activation. Science1999; 285: 221.
9. von Willebrand E, Lautenschlager I, Krogerus L, et al. Adhesion molecules and activation markers in acute rejection of human renal allo-grafts. Transpl Immunol 1996; 4: 57.
10. Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. Br Med Bull 2004; 70: 71.
11. Goodman RS, Kirton CM, Oostingh GJ, et al. PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. Transplantation 2008; 85: 471.
12. Balduini CL, FrassoniF,NorisP,etal. Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. Br J Haematol 2001; 114: 951.
13. Behar E, Chao NJ, Hiraki DD, et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med 1996; 334: 286.
14. Grumet FC, Hiraki DD, Brown BWM, et al. CD31 mismatching affects marrow transplantation outcome. Biol Blood Marrow Transplant 2001; 7: 503.
15. MaruyaE, Saji H,Seki S, et al. Evidence that CD31, CD49b, and CD62L are immunodominant minor histocompatibility antigensinHLA identical sibling bone marrow transplants. Blood 1998; 92: 2169.
16. Katagiri T, Shiobara S, Nakao S, et al. Mismatch of minor histocom-patibility antigen contributes to a graft-versus-leukemia effect rather than to acute GVHD, resulting in long-term survival after HLA-identical stem cell transplantation in Japan. Bone Marrow Transplant 2006; 38: 681.
17. Tedder TF, Penta AC, Levine HB, et al. Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. J Immunol 1990; 144: 532.
18. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983; 304: 30.
19. Ley K, Tedder TF, Kansas GS. L-selectin can mediate leukocyte rolling in untreated mesenteric venulesinvivo independentofE-orP-selectin. Blood 1993; 82: 1632.
20. Kansas GS. Selectins and their ligands: Current concepts and controversies. Blood 1996; 88: 3259.
21. Newman PJ. The biology of PECAM-1. J Clin Invest 1997; 99: 3.
22. Wang Y, Su X, Sorenson CM, et al. Tissue-specific distributions of alternatively spliced human PECAM-1 isoforms. Am J Physiol Heart Circ Physiol 2003; 284: H1008.
23. Goodman RS, Ewing J, Evans PC, et al. Donor CD31 genotype and its association with acute graft-versus-host disease in HLA identical sibling stem cell transplantation. Bone Marrow Transplant 2005; 36: 151.
24. Bowen MA, Patel DD, Li X, et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 1995; 181: 2213.
25. van Kempen LC, Nelissen JM, Degen WG, et al. Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-AL-CAM interaction. J Biol Chem 2001; 276: 25783.
26. Levesque MC, Heinly CS, Whichard LP, et al. Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium. Arthritis Rheum 1998; 41: 2221.
27. Zimmerman AW, JoostenB, TorensmaR,etal. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood 2006; 107: 3212.
28. Aruffo A, Bowen MA, Patel DD, et al. CD6-ligand interactions: A paradigm for SRCR domain function? Immunol Today 1997; 18: 498.
29. Aruffo A, Melnick MB, Linsley PS, et al. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. J Exp Med 1991; 174: 949.
30. Gimferrer I, Calvo M, Mittelbrunn M, et al. Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol 2004; 173: 2262.
31. Hassan NJ, Barclay AN, Brown MH. Frontline: Optimal T cell activation requires the engagement of CD6 and CD166. Eur J Immunol 2004; 34: 930.
32. Dupont WD, Plummer WD Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19: 589.
33. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
34. Bidwell JL, Bidwell EA, Savage DA, et al. A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DQ alleles, including DRw10. Transplantation 1988; 45: 640.
35. Cox DR. Regression models and life-tables. J Royal Stat Soc 1972; 34: 187.
36. Cavanagh G, Chapman CE, Carter V, et al. Donor CD31 genotype impacts on transplant complications after human leukocyte antigen-matched sibling allogeneic bone marrow transplantation. Transplantation 2005; 79: 602.
37. Opelz G. Non-HLA transplantation immunity revealed by lymphocy-totoxic antibodies. Lancet 2005; 365: 1570.
38. Terasaki PI. Deduction of the fraction of immunologic and non-immunologic failure in cadaver donor transplants. Clin Transpl 2003: 449.
39. McLaren AJ, Marshall SE, Haldar NA, et al. Adhesion molecule polymorphisms in chronic renal allograft failure. Kidney Int 1999; 55: 1977.
40. Khazen D, Jendoubi-Ayed S, Gorgi Y, et al. Adhesion molecule polymorphisms in acute renal allograft rejection. Transplant Proc 2007; 39: 2563.
41. Robbins FM, Hartzman RJ. CD31/PECAM-1 genotyping and haplo-type analyses show population diversity. Tissue Antigens 2007; 69: 28.
42. Westermann J, Engelhardt B, Hoffmann JC. Migration of T cells in vivo: Molecular mechanisms and clinical implications. Ann Intern Med 2001; 135: 279.
43. Reddy P,Ferrara JL. Immunobiologyofacute graft-versus-host disease. Blood Rev 2003; 17: 187.
44. Wakelin MW, Sanz MJ, Dewar A, et al. Ananti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane. J Exp Med 1996; 184: 229.
45. Spierings E, Wieles B, Goulmy E. Minor histocompatibility antigens\Big in tumour therapy. Trends Immunol 2004; 25: 56.
46. Goulmy E. Minor histocompatibility antigens: From transplantation problems to therapy of cancer. Hum Immunol 2006; 67: 433.
47. Heinold A, Opelz G, Scherer S, et al. Role of minor histocompatibility antigens in renal transplantation. Am J Transplant 2008; 8: 95.
48. Gerrits JH, van de Wetering J, Postma S, et al. Stable T-cell reactivity after successful tapering of azathioprine in HLA-identical living-related kidney transplant recipients despite minor histocompatibil-ity antigen mismatches. Nephrol Dial Transplant 2007; 22: 353.
49. Freely associating. Nat Genet 1999; 22: 1.
50. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005; 366: 1315.